Prosecution Insights
Last updated: November 15, 2026
Application No. 17/781,452

VARIANT CAS9

Non-Final OA §101§112
Filed
Jun 01, 2022
Priority
Feb 25, 2020 — HU P2000068 +4 more
Examiner
ALLEN, SARAH ELIZABETH
Art Unit
1637
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BIOSPIRÁL-2006 FEJLESZTÕ ÉS TANÁCSADÓ KFT.
OA Round
3 (Non-Final)
57%
Grant Probability
Moderate
3-4
OA Rounds
90%
With Interview

Examiner Intelligence

Grants 57% of resolved cases
57%
Career Allowance Rate
17 granted / 30 resolved
-3.3% vs TC avg
Strong +33% interview lift
Without
With
+33.3%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
49 currently pending
Career history
95
Total Applications
across all art units

Office Action

§101 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s response of 08/03/2026, including replacement drawings, has been received and entered into the application file. Claims 2-10, 12, and 15-17 were amended in the claim set filed 08/03/2026. Claim 20 was added in the claim set filed 08/03/2026. Prosecution on the merits of this application is reopened on claims 1-20. The finality of the office action dated 06/02/2026 is hereby withdrawn. New grounds of rejection are set forth below. Election/Restrictions Applicant's previous election with traverse of Group I (claims 1-16) with a species election of Blackjack-SpCas9 (SEQ ID NO: 13) in the reply filed on 08/26/2025 is acknowledged. The traversal was on the grounds that the cited art in the restriction requirement dated 06/26/2025 (CA 3069296 A1; hereinafter Kim; previously cited) does not teach or suggest all the elements of claim 1. After searching the patent and non-patent literature for the elected invention and species, this was found persuasive. Accordingly, the restriction requirement dated 06/26/2025 was previously withdrawn, as acknowledged by Applicant in the reply filed 04/20/2026. Status of Prior Objections/Rejections RE: Drawings ►The drawings were previously objected to for various informalities. The replacement drawings have obviated the basis of the objection of record. The objection of record is hereby withdrawn. RE: Claim Objections ►Claims 3-6, 9, 10, 12, 16, and 17 were previously objected to because of various informalities. The amendments to the instant claim set have obviated the basis of the objections of record. The objections of record are hereby withdrawn. RE: Claim Rejections - 35 USC § 112(b) ►Claims 5, 7-9, 12, and 15-18 were previously rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The amendments to the instant claim set have obviated the basis of the rejection of record. The rejection of record is hereby withdrawn. New/Maintained Grounds of Objection/Rejection Nucleotide and/or Amino Acid Sequence Disclosures REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES Items 1) and 2) provide general guidance related to requirements for sequence disclosures. 37 CFR 1.821(c) requires that patent applications which contain disclosures of nucleotide and/or amino acid sequences that fall within the definitions of 37 CFR 1.821(a) must contain a "Sequence Listing," as a separate part of the disclosure, which presents the nucleotide and/or amino acid sequences and associated information using the symbols and format in accordance with the requirements of 37 CFR 1.821 - 1.825. This "Sequence Listing" part of the disclosure may be submitted: In accordance with 37 CFR 1.821(c)(1) via the USPTO patent electronic filing system (see Section I.1 of the Legal Framework for Patent Electronic System (https://www.uspto.gov/PatentLegalFramework), hereinafter "Legal Framework") as an ASCII text file, together with an incorporation-by-reference of the material in the ASCII text file in a separate paragraph of the specification as required by 37 CFR 1.823(b)(1) identifying: the name of the ASCII text file; ii) the date of creation; and iii) the size of the ASCII text file in bytes; In accordance with 37 CFR 1.821(c)(1) on read-only optical disc(s) as permitted by 37 CFR 1.52(e)(1)(ii), labeled according to 37 CFR 1.52(e)(5), with an incorporation-by-reference of the material in the ASCII text file according to 37 CFR 1.52(e)(8) and 37 CFR 1.823(b)(1) in a separate paragraph of the specification identifying: the name of the ASCII text file; the date of creation; and the size of the ASCII text file in bytes; In accordance with 37 CFR 1.821(c)(2) via the USPTO patent electronic filing system as a PDF file (not recommended); or In accordance with 37 CFR 1.821(c)(3) on physical sheets of paper (not recommended). When a “Sequence Listing” has been submitted as a PDF file as in 1(c) above (37 CFR 1.821(c)(2)) or on physical sheets of paper as in 1(d) above (37 CFR 1.821(c)(3)), 37 CFR 1.821(e)(1) requires a computer readable form (CRF) of the “Sequence Listing” in accordance with the requirements of 37 CFR 1.824. If the "Sequence Listing" required by 37 CFR 1.821(c) is filed via the USPTO patent electronic filing system as a PDF, then 37 CFR 1.821(e)(1)(ii) or 1.821(e)(2)(ii) requires submission of a statement that the "Sequence Listing" content of the PDF copy and the CRF copy (the ASCII text file copy) are identical. If the "Sequence Listing" required by 37 CFR 1.821(c) is filed on paper or read-only optical disc, then 37 CFR 1.821(e)(1)(ii) or 1.821(e)(2)(ii) requires submission of a statement that the "Sequence Listing" content of the paper or read-only optical disc copy and the CRF are identical. Specific deficiencies and the required response to this Office Action are as follows: Specific deficiency – Nucleotide and/or amino acid sequences appearing in the specification are not identified by sequence identifiers in accordance with 37 CFR 1.821(d). From line 30 of page 6 to line 5 of page 7, numerous insertion sequences are disclosed, including (Gly)m, wherein m is an integer from 1 to 6 (page 6, line 32) and (Gly)m, wherein m is an integer from 1 to 4 (page 7, line 4). These insertion sequences are also recited at instant claim 7. It is thus considered that these insertion sequences read on a chain of multiple amino acid residues. As set forth in MPEP § 2422.01, amino acid sequences with four or more specifically defined amino acids are required to be included in a sequence listing. Required response – Applicant must provide: A substitute specification in compliance with 37 CFR 1.52, 1.121(b)(3) and 1.125 inserting the required sequence identifiers, consisting of: A copy of the previously-submitted specification, with deletions shown with strikethrough or brackets and insertions shown with underlining (marked-up version); A copy of the amended specification without markings (clean version); and A statement that the substitute specification contains no new matter. Claim Objections Claims 1-20 are objected to because of the following informalities: Claim 1 recites several wherein clauses, the first of which is not preceded by a comma, which should be present at line 5. It would be remedial to amend the instant claim language to include a comma at line 5 preceding the following wherein clause. Claims 2-20 all directly or indirectly depend from instant claim 1 and inherit the objection thereof, as they do not resolve the basis of the objection. Claim 7 recites a number of possible insertion sequences, including (Gly)m, wherein m is an integer from 1 to 6. It is thus considered that these insertion sequences read on a chain of multiple amino acid residues. As set forth in MPEP § 2422.01, amino acid sequences with four or more specifically defined amino acids are required to be included in a sequence listing and identified accordingly. It would be remedial to amend the instant claim language to properly include sequence identifiers as necessary (i.e. four or more specifically enumerated amino acid residues). Claim 9 recites several sequences, which are not separated by commas. Furthermore, lines 3 and 4 currently recite “Lys 1003, Leu1004, and Glu1007 are marked in bold and underlined, respectively” and “Tyr1013, Leu1004 and Asp1017 are marked in bold, respectively.” However, each of Lys 1003, Leu1004, and Glu 1007 are marked in bold and underlined, thereby rendering the word “respectively” improper. Similarly, each of Tyr1013, Leu1004, and Asp1017 are marked in bold, thereby rendering the word “respectively” improper. It would be remedial to amend the instant claim language to recite, for example “Lys 1003, Leu1004, and Glu1007 are marked in bold and underlined in each of the following sequences” (bolded emphasis added) and “Tyr 1013, Leu1004 and Asp1017 are marked in bold in each of the following sequences” (bolded emphasis added). It would be remedial to amend the instant claim language such that each recited sequence is properly separated by a comma. Claim 10 depends from instant claim 9 and inherits the objection thereof, as it does not resolve the basis of the objection. Furthermore, the parenthetical phrase “(i.e. replaces)” recited in lines 4-5 of instant claim 10 is redundant. It would be remedial to replace the parenthetical phrase “(i.e. replaces)” with “wherein said sequence is present in the position of” or “wherein said sequence replaces.” Appropriate correction is required. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Section 33(a) of the America Invents Act reads as follows: Notwithstanding any other provision of law, no patent may issue on a claim directed to or encompassing a human organism. Claim 15 is rejected under 35 U.S.C. 101 and section 33(a) of the America Invents Act as being directed to or encompassing a human organism. See also Animals - Patentability, 1077 Off. Gaz. Pat. Office 24 (April 21, 1987) (indicating that human organisms are excluded from the scope of patentable subject matter under 35 U.S.C. 101). The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. With regard to claim 15, which recites “a host cell comprising the nucleic acid of claim 13 or a vector comprising said nucleic acid,” the broadest reasonable interpretation of the term “cell” embraces a human having the cell. The instant specification envisions host cells such as bacterial, yeast, insect, or mammalian host cells such as human host cells comprising the nucleic acids described therein (page 13, lines 6-10; page 14, line 39), which are not limited to in vitro applications. Additionally, the specification teaches that cells are sampled from a human and modified using the vector, after which the modified cells are re-introduced into the organism (paragraph spanning pages 14-15; page 15, lines 7-13 and 32-36). Therefore, under broadest reasonable interpretation of the claim language and in view of the disclosure of the instant specification, the term “cell” in claim 15 embraces a human having the cell. It would be remedial to amend the instant claim to recite “an isolated host cell” (bolded emphasis added) to avoid the claim embracing a human organism. Claim Rejections - 35 USC § 112(a) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim 8 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Claim 8 is drawn to a set of fidelity-increasing mutations of an increased fidelity variant, wherein said fidelity-increasing mutations of an increased fidelity variant many be selected from the group consisting of SpCas9-HF1, HypaSpCas9, evoSpCas9, HiFi SpCas9, Sniper SpCas9, eSpCas9, Hypa2SpCas9, and HeFSpCas9 or any fidelity increasing mutation in an increased fidelity Cas9. The rejected claims thus comprise a set of mutations, including unidentified/unspecified mutations, that increase Cas9 fidelity. To provide adequate written description and evidence of possession of a claimed genus, the specification must provide sufficient distinguishing identifying characteristics of the genus. The factors to be considered include disclosure of a complete or partial structure, physical and/or chemical properties, functional characteristics, structure/function correlation, and any combination thereof. The specification describes SpCas9-HF1, HypaSpCas9, evoSpCas9, HiFi SpCas9, Sniper SpCas9, eSpCas9, Hypa2SpCas9, and HeFSpCas9, as well as Blackjack mutations thereof (Table 8). No description is provided of all possible fidelity increasing mutations in an increased fidelity Cas9. Even if one accepts that the examples described in the specification meet the claim limitations of the rejected claims with regard to structure and function, the examples are only representative of the increased fidelity variants disclosed therein (i.e. at Table 8). The results are not necessarily predictive of any fidelity increasing mutation in an increased fidelity Cas9. Thus, it is impossible for one to extrapolate from the few examples described herein those fidelity increasing mutations in an increased fidelity Cas9 that would necessarily meet the structural/functional characteristics of the rejected claims. The prior art does not appear to offset the deficiencies of the instant specification in that it does not describe a set of fidelity increasing mutations in an increased fidelity Cas9 that would necessarily meet the structural/functional characteristics of the rejected claims. Therefore, the skilled artisan would have reasonably concluded applicants were not in possession of the claimed invention for claim 8. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 18 and 19 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. With regard to claim 18, which recites “the variant Cas9 protein of claim 9, comprising an amino acid sequence that has at least 95% sequence identity to the corresponding amino acid sequence,” the limitation “the corresponding amino acid sequence” lacks antecedent basis. It would be remedial to amend the instant claim such that there is sufficient antecedent basis and further that it is clear to those of ordinary skill in the art what “corresponding amino acid sequence” is being invoked in the instant claim set, for example as set forth below. While instant claim 1 recites “a corresponding surface loop having a wild type sequence,” this does not appear to be “the corresponding sequence” of claim 18, which is drawn to a Cas9 protein, not just a surface loop thereof. Additionally, the instant claim requires a particular percent identity to an unnamed Cas9 sequence identified only as a “corresponding amino acid sequence.” The metes and bounds are not clear, because one cannot determine percent identity to an unspecified base sequence. With regard to claim 19, which recites “the variant Cas9 protein of claim 9, comprising an amino acid sequence that has at least 95% sequence identity to the corresponding amino acid sequence,” as set forth above, the instant claim requires a particular percent identity to an unnamed Cas9 sequence identified only as a “corresponding amino acid sequence.” The metes and bounds are not clear, because one cannot determine percent identity to an unspecified base sequence. It would be remedial to amend the instant claim language to clarify the indefiniteness issues noted above, for example by replacing the phrase “the corresponding amino acid sequence” with the phrase “the sequence of SEQ ID NO: 1, 2, or 3” (for example) thereby clearly informing those of ordinary skill in the art of the metes and bounds of protection sought by the instant claim set. Claim Rejections - 35 USC § 112(d) The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 3, 4, 10, and 19 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 3 depends from claim 1. Claim 1 is drawn to a variant of a Streptococcus pyogenes Cas9 (SpCas9) protein. However, instant claim 3 appears to broaden the scope of the instant claims from SpCas9 to any Cas9 protein by reciting “or a corresponding sequence of a wild type Cas9 protein comprising said surface loop,” which notably does not limit the claimed Cas9 protein to SpCas9. Thus, it cannot be considered that claim 3 includes all the limitations of instant claim 1, as it broadens the scope of the claims. Claim 4 depends from claim 1. Claim 1 is drawn to a variant of a Streptococcus pyogenes Cas9 (SpCas9) protein. However, instant claim 4 appears to broaden the scope of the instant claims from SpCas9 to any Cas9 protein by reciting “or a corresponding sequence of a wild type Cas9 protein comprising said surface loop,” which notably does not limit the claimed Cas9 protein to SpCas9. Thus, it cannot be considered that claim 4 includes all the limitations of instant claim 1, as it broadens the scope of the claims. Claim 10 depends from claim 9, which also depends from claim 1. Claim 1 is drawn to a variant of a Streptococcus pyogenes Cas9 (SpCas9) protein, while claim 9 further limits said variant of an SpCas9 protein to further comprise an increased fidelity variant. However, instant claim 10 appears to broaden the scope of the instant claims from SpCas9 to any Cas9 protein by reciting “or a corresponding sequence of a wild type Cas9 protein comprising said surface loop,” which notably does not limit the claimed Cas9 protein to SpCas9. Thus, it cannot be considered that claim 10 includes all the limitations of instant claims 1 and 9, as it broadens the scope of the claims. Claim 19 depends from instant claim 10 and does not overcome the basis of the rejection under 35 U.S.C. 112(d) set forth above and therefore inherits the rejection of instant claim 10. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Allowable Subject Matter The following is a statement of reasons for the indication of allowable subject matter: While Cas9 and variants thereof (including high-fidelity variants) are well-known in the art, as set forth in the instant specification and supported by a search of both the patent and non-patent literature, the instantly-claimed Cas9 variant comprising a mutation in the surface loop as set forth at instant claim 1 does not appear to have been known in the field as of the effective filing date, nor does the state of the art as of the effective filing date provide sufficient motivation to arrive at the instant invention. While Slaymaker et al., 2016 (of record) does disclose that the RuvC domain (which comprises the region of mutated amino acid residues set forth in the instant application per UniProt entry Q99ZW2) is implicated in stabilizing the nontarget strand of the target DNA and is thus a viable target to alter in order to require more stringent Watson-Crick base pairing between the RNA guide and the target DNA strand (page 84, text column 2, paragraph 2), they do not disclose the instantly claimed mutation. Additionally, CA 3069296 A1 (hereinafter Kim; of record) discloses the deletion of one or more amino acids in region 2-3 of SpCas9 to improve target specificity (page 12, lines 16-19; page 94, lines 9-11), which completely encompasses the instantly claimed range of 6-12 amino acids and must necessarily produce a Cas9 with the instantly claimed structure and function (see MPEP § 2114 and § 2173.05(g)), as set forth in the restriction requirement dated 06/26/2025. However, as Applicant noted in the reply dated 08/26/2025, this disclosure constitutes “a laundry list of possible mutated amino acids”; furthermore, Kim does not motivate the deletion of 6-12 amino acids specifically, as instantly claimed. In summary, it does not appear that a person having ordinary skill in the art would have been sufficiently motivated by what was known in the field at the time of the effective filing date of the claimed invention to alter a wild-type Cas9 to arrive at the instantly claimed variant Cas9. However, there are formal requirements outstanding regarding the instant claims, as well as rejections under 35 U.S.C. 112(b) and 35 U.S.C. 112(d). As allowable subject matter has been indicated, applicant's reply must either comply with all formal requirements or specifically traverse each requirement not complied with. See 37 CFR 1.111(b) and MPEP § 707.07(a). Furthermore, the rejections under 35 U.S.C. 112(b) and 35 U.S.C. 112(d) must be overcome prior to allowance and issue. Conclusion Claims 3, 4, 8, 10, 15, 18, and 19 are rejected. Claims 1, 2, 5-7, 11-14, 16-17, and 20 are objected to. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sarah E Allen whose telephone number is (571)272-0408. The examiner can normally be reached M-F 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer Dunston can be reached at 571-272-2916. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SARAH E ALLEN/Examiner, Art Unit 1637 /Jennifer Dunston/Supervisory Patent Examiner, Art Unit 1637
Read full office action

Prosecution Timeline

Jun 01, 2022
Application Filed
Nov 19, 2025
Non-Final Rejection mailed — §101, §112
Apr 20, 2026
Response Filed
Jun 02, 2026
Final Rejection mailed — §101, §112
Aug 03, 2026
Response after Non-Final Action
Sep 17, 2026
Non-Final Rejection mailed — §101, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12774464
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF METHYLATION-CONTROLLED J-PROTEIN (MCJ)
4y 2m to grant Granted Oct 27, 2026
Patent 12758652
COMPOSITIONS AND METHODS FOR UPREGULATING ISOFORMS OF DYSTROPHIN AS THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY (DMD)
4y 6m to grant Granted Oct 13, 2026
Patent 12735703
OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
4y 5m to grant Granted Sep 15, 2026
Patent 12703874
METHODS OF TREATING HEARING LOSS USING A SECRETED TARGET PROTEIN
4y 6m to grant Granted Aug 11, 2026
Patent 12649922
Novel Retinitis Pigmentosa Treatment
1y 10m to grant Granted Jun 09, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
57%
Grant Probability
90%
With Interview (+33.3%)
High
PTA Risk
Based on 30 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month